Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis

Phase 3

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Placebo
Drug: Ixekizumab
Drug: Etanercept

Registration Number: NCT03073200

Lead Sponsor: Eli Lilly and Company

Brief Summary: The purpose of this study is to evaluate the safety and efficacy of ixekizumab in pediatric participants with moderate-to-severe plaque psoriasis.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 201

Inclusion Criteria

Have a diagnosis of moderate-to-severe plaque-type psoriasis for at least 6 months prior to baseline as determined by the investigator.
Have Psoriasis Area and Severity Index (PASI) score ≥12 and a Static Physician Global Assessment (sPGA) ≥3 and body surface area involvement ≥10% at screening and baseline.
Are candidates for phototherapy or systemic treatment or considered by the investigator as not adequately controlled by topical therapies.
Male subjects agree to use a reliable method of birth control during the study.
Female subjects: Participants of childbearing age or childbearing potential who are sexually active who test negative for pregnancy must be counselled and agree to use either 1 highly effective method of contraception or 2 acceptable methods of contraception combined for the duration of the study and for at least 12 weeks following the last dose of study drug, or remain abstinent during the study and for at least 12 weeks following the last dose of study drug.
Both the child or adolescent and a parent or legal guardian are able to understand and fully participate in the activities of the clinical study and sign their assent and consent, respectively.
All immunizations are up-to-date in agreement with current immunization guidelines as noted by country specific paediatric authorities (e.g., the American Academy of Paediatrics). Note, subjects who are not up to date or have never been immunized are not to be enrolled in the trial.

Exclusion Criteria

Have pustular, erythrodermic, and/or guttate forms of psoriasis.
Have drug-induced psoriasis.
Have clinical and/or laboratory evidence of untreated latent or active tuberculosis (TB).
Participants with a documented history of immune deficiency syndrome.
Have any other active or recent infection, including chronic or localized infections, within 4 weeks of baseline.
Subjects with a known history of malignancy, lymphoproliferative disease, including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy and/or splenomegaly unless ruled out by biopsy.
Have used any therapeutic agent targeted at reducing interleukin-17.
Have received other therapies within the specified time frames prior to screening (see below):
- adalimumab and infliximab 60 days, abatacept 90 days, anakinra 7 days, or any other biologic disease-modifying antirheumatic drug 5 half-lives.
- systemic therapy for psoriasis and psoriatic arthritis (PsA) (other than above, eg, methotrexate, cyclosporine), phototherapy (eg, photochemotherapy [psoralen plus ultraviolet A]) in the previous 4 weeks.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Placebo given SC during the double-blind treatment period and then ixekizumab given SC during the open-label maintenance period.
Ixekizumab	Ixekizumab	Ixekizumab given subcutaneously (SC) during the double-blind treatment period and the open-label maintenance period.
Open-Label Etanercept	Etanercept	Etanercept given SC during the double-blind treatment period and then ixekizumab given SC during the open-label maintenance period. Participants will only be randomized to etanercept in countries where it is approved for severe pediatric psoriasis treatment.

Primary Outcome Measures

Name	Time	Method
Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75) (Placebo and Ixekizumab)	Week 12	PASI combines assessments of the extent of body surface involvement in 4 regions (head \& neck(h), trunk(t), arms(u), legs(l)) \& severity of scaling (S), redness (R), \& plaque induration/infiltration (thickness, T) in each region. Severity is rated for each index (R, S, T) on a 0-4 scale (0 for no involvement up to 4 for severe involvement): 0 = none, 1 = slight, 2 = mild, 3 = moderate, 4 = severe Fraction of total body surface area (BSA) affected is graded on a 0-6 scale (0 for no involvement to 6 for 90% - 100% involvement): 0 = 0% (clear), 1 = \>0% to \<10%, 2 = 10% to \<30%, 3 = 30% to \<50%, 4 = 50% to \<70%, 5 = 70% to 90%, 6 = 90% to 100%. Overall score ranges from 0 (no psoriasis) to 72 (most severe disease).
Percentage of Participants With a Static Physician Global Assessment (sPGA) (0,1) (Placebo and Ixekizumab)	Week 12	Static Physician Global Assessment (sPGA): The physician's global assessment of the Participant's psoriasis lesions at a given time point. Plaques are assessed for induration, erythema, and scaling, and an overall rating of psoriasis severity is given using the anchors of clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA assessed as either 0 or 1 represents a clinically meaningful response of minimal plaque severity or complete resolution of plaque psoriasis.

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants With a Static Physician Global Assessment (sPGA) (0,1)	Week 4	Static Physician Global Assessment (sPGA): The physician's global assessment of the Participant's psoriasis lesions at a given time point. Plaques are assessed for induration, erythema, and scaling, and an overall rating of psoriasis severity is given using the anchors of clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA assessed as either 0 or 1 represents a clinically meaningful response of minimal plaque severity or complete resolution of plaque psoriasis.
Change From Baseline on the Psoriasis Scalp Severity Index (PSSI)	Baseline, Week 12	The scalp was assessed for erythema (redness), induration (hardness), and desquamation (shedding of skin) and percentage of area affected as follows: Erythema, Induration and Desquamation: 0 = Absent 1. = Slight 2. = Moderate 3. = Severe 4. = Severest Possible Percent of Scalp Involved: 1. = \<10% 2. = 10% - 29% 3. = 30% - 49% 4. = 50% - 69% 5. = 70% - 89% 6. = 90% - 100% The PSSI score is a composite score derived from the sum of the scores for erythema, induration and desquamation multiplied by the score for the extent of scalp area involved (percent of scalp involved). The range is 0 (no psoriasis) to 72 (Most severe Disease). LSMean was calculated using treatment, region, baseline sPGA score, baseline weight category, baseline value, visit, treatment-by-visit, and baseline-by-visit interactions as fixed factors.
Percentage of Participants With a sPGA (0)	Week 12	Static Physician Global Assessment (sPGA): The physician's global assessment of the Participant's psoriasis lesions at a given time point. Plaques are assessed for induration, erythema, and scaling, and an overall rating of psoriasis severity is given using the anchors of clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA assessed as either 0 or 1 represents a clinically meaningful response of minimal plaque severity or complete resolution of plaque psoriasis. An sPGA assessed as 0 represents a clinically important endpoint indicating complete resolution of plaque psoriasis.
Percentage of Participants With an Improvement of ≥4 in Those Who Had a Baseline Itch Numeric Rating Scale (NRS) Score of ≥4	Week 12	Itch Numeric Rating Scale (NRS): is a single-item, patient-reported outcome (PRO) measure designed to capture the overall severity of a participant's itching due to his/her psoriasis by having the patient circle the integer that describes the worst level of itching in the past 24 hours on an 11-point NRS anchored at 0 representing "no itching" and 10 representing "worst itch imaginable.
Percentage of Participants Achieving Children's Dermatology Life Quality Index (CDLQI)/Dermatology Life Quality Index (DLQI) (0/1)	Week 12	DLQI is a validated, dermatology-specific, patient reported measure that evaluates participant's health-related quality of life. It consists of 10 items that are grouped in 6 domains: symptoms \& feelings, daily activities, leisure, work \& school , personal relationships, \& treatment. The recall period of this scale is over the "last week." Response categories and corresponding scores are: Very much = 3, A lot = 2, A little = 1, Not at all = 0, Not relevant = 0. A DLQI total score is calculated by summing all 10 items responses, and has a range of 0 to 30 (higher scores are indicative of greater impairment). CDLQI questionnaire is designed for use in children (4 to 16 years of age). It consists of 10 items that are grouped into 6 domains: symptoms \& feelings, leisure, school or holidays, personal relationships, sleep, \& treatment. A CDLQI total score is calculated by summing all 10 items responses, and has a range of 0 to 30 (higher scores are indicative of greater impairment).
Percentage of Participants With a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90)	Week 12	PASI combines assessments of the extent of body surface involvement in 4 regions (head \& neck(h), trunk(t), arms(u), legs(l)) \& severity of scaling (S), redness (R), \& plaque induration/infiltration (thickness, T) in each region. Severity is rated for each index (R, S, T) on a 0-4 scale (0 for no involvement up to 4 for severe involvement): 0 = none, 1 = slight, 2 = mild, 3 = moderate, 4 = severe Fraction of total BSA affected is graded on a 0-6 scale (0 for no involvement to 6 for 90% - 100% involvement): 0 = 0% (clear), 1 = \>0% to \<10%, 2 = 10% to \<30%, 3 = 30% to \<50%, 4 = 50% to \<70%, 5 = 70% to 90%, 6 = 90% to 100%.Overall score ranges from 0 (no psoriasis) to 72 (most severe disease).
Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75)	Week 4	PASI combines assessments of the extent of body surface involvement in 4 regions (head \& neck(h), trunk(t), arms(u), legs(l)) \& severity of scaling (S), redness (R), \& plaque induration/infiltration (thickness, T) in each region. Severity is rated for each index (R, S, T) on a 0-4 scale (0 for no involvement up to 4 for severe involvement): 0 = none, 1 = slight, 2 = mild, 3 = moderate, 4 = severe Fraction of total BSA affected is graded on a 0-6 scale (0 for no involvement to 6 for 90% - 100% involvement): 0 = 0% (clear), 1 = \>0% to \<10%, 2 = 10% to \<30%, 3 = 30% to \<50%, 4 = 50% to \<70%, 5 = 70% to 90%, 6 = 90% to 100%. Overall score ranges from 0 (no psoriasis) to 72 (most severe disease).
Percentage of Participants With a 100% Improvement in Psoriasis Area and Severity Index (PASI 100)	Week 12	PASI combines assessments of the extent of body surface involvement in 4 regions (head \& neck(h), trunk(t), arms(u), legs(l)) \& severity of scaling (S), redness (R), \& plaque induration/infiltration (thickness, T) in each region. Severity is rated for each index (R, S, T) on a 0-4 scale (0 for no involvement up to 4 for severe involvement): 0 = none, 1 = slight, 2 = mild, 3 = moderate, 4 = severe Fraction of total BSA affected is graded on a 0-6 scale (0 for no involvement to 6 for 90% - 100% involvement): 0 = 0% (clear), 1 = \>0% to \<10%, 2 = 10% to \<30%, 3 = 30% to \<50%, 4 = 50% to \<70%, 5 = 70% to 90%, 6 = 90% to 100%. Overall score ranges from 0 (no psoriasis) to 72 (most severe disease).
Percentage of Participants With a Static Physician Global Assessment (sPGA) (0,1) (Etanercept Approved Countries)	Week 12	Static Physician Global Assessment (sPGA): The physician's global assessment of the Participant's psoriasis lesions at a given time point. Plaques are assessed for induration, erythema, and scaling, and an overall rating of psoriasis severity is given using the anchors of clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA assessed as either 0 or 1 represents a clinically meaningful response of minimal plaque severity or complete resolution of plaque psoriasis.
Change From Baseline on the Nail Psoriasis Severity Index (NAPSI)	Baseline, Week 12	NAPSI is a numeric, reproducible, objective tool for evaluation of nail psoriasis. This scale was used to evaluate the severity of nail bed psoriasis \& nail matrix psoriasis by area of involvement in the nail unit. Both fingernail \& toenail involvement were assessed.The nail is divided with imaginary horizontal \& longitudinal lines into quadrants. Each nail is given a score for nail bed psoriasis (0 to 4) \& nail matrix psoriasis (0 to 4), depending on the presence (score of 1) or absence (score of 0) of any of the features of nail bed \& nail matrix psoriasis in each quadrant: 0 = None 1. = present in one quadrant of nail 2. = present in two quadrants of nail 3. = present in three quadrants of nail 4. = present in four quadrants of nail NAPSI score of a nail is the sum of scores in nail bed \& nail matrix from each quadrant (maximum of 8). Each nail is evaluated, \& the sum of all the fingernails and toenails is the total NAPSI score ranging from 0 to 160 (No to Severe nail Psoriasis)
Change From Baseline on the Palmoplantar Psoriasis Severity Index (PPASI)	Baseline, Week 12	PPASI was used if the participant has palmoplantar psoriasis at baseline. Both the palms \& soles on each hand \& foot was assessed for erythema, induration, desquamation \& percentage of area affected as follows: Erythema (E), Induration (I), \& Desquamation (D):0 = None, 1 = Slight, 2 = Moderate, 3 = Severe, 4 = Very Severe Percent of Palm and Sole Area Covered: 0 = None, 1 = \<10%, 2 = 10% - 29%, 3 = 30% - 49%, 4 = 50% - 69%, 5 = 70% - 89%, 6 = 90% - 100% PPASI score is a composite score derived from the sum scores for E, I, \& D multiplied by a score for the extent of palm \& sole area involvement. The range is 0 (no psoriasis) to 72 (most severe disease).
Number of Participants With Anti-Ixekizumab Antibodies	Baseline through Week 48	A treatment emergent - antidrug antibody (TE-ADA) positive participant were defined as: 1. a participant with a \>= 4-fold increase over a positive baseline antibody titer; or 2. for a negative baseline titer, a participant with an increase from the baseline to a level of \>= 1:10.
Pharmacokinetics (PK): Trough Ixekizumab Concentration at Steady State (Ctrough ss)	Week 12	Pharmacokinetics (PK): Trough Ixekizumab Concentration at Steady State (Ctrough ss).
Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75) (Etanercept Approved Countries)	Week 12	PASI combines assessments of the extent of body surface involvement in 4 regions (head \& neck(h), trunk(t), arms(u), legs(l)) \& severity of scaling (S), redness (R), \& plaque induration/infiltration (thickness, T) in each region. Severity is rated for each index (R, S, T) on a 0-4 scale (0 for no involvement up to 4 for severe involvement): 0 = none, 1 = slight, 2 = mild, 3 = moderate, 4 = severe Fraction of total BSA affected is graded on a 0-6 scale (0 for no involvement to 6 for 90% - 100% involvement): 0 = 0% (clear), 1 = \>0% to \<10%, 2 = 10% to \<30%, 3 = 30% to \<50%, 4 = 50% to \<70%, 5 = 70% to 90%, 6 = 90% to 100%. Overall score ranges from 0 (no psoriasis) to 72 (most severe disease).

Trial Locations

Locations (69): Northwestern University
🇺🇸
Chicago, Illinois, United States
Modern Research Associates PLLC
🇺🇸
Dallas, Texas, United States
Hospital Univ. Dr. Jose Eleuterio Gonzalez
🇲🇽
Monterrey, Nuevo León, Mexico
GCM Medical Group PSC
🇵🇷
San Juan, Puerto Rico
Office of Dr. Samuel Sanchez PSC
🇵🇷
Caguas, Puerto Rico
Grupo Dermatologico de Carolina
🇵🇷
Carolina, Puerto Rico
Medical University of South Carolina
🇺🇸
Charleston, South Carolina, United States
Children's National Medical Center
🇺🇸
Washington, District of Columbia, United States
RM Pharma Specialists S.A. de C.V.
🇲🇽
Distrito Federal, Mexico
University of South Florida
🇺🇸
Tampa, Florida, United States
University of Alabama at Birmingham
🇺🇸
Birmingham, Alabama, United States
Oregon Dermatology and Research Center
🇺🇸
Portland, Oregon, United States
Oregon Health and Science University
🇺🇸
Portland, Oregon, United States
Texas Dermatology and Laser Specialists
🇺🇸
San Antonio, Texas, United States
Tien Q. Nguyen, MD inc. DBA First OC Dermatology
🇺🇸
Fountain Valley, California, United States
Olympian Clinical Research
🇺🇸
Clearwater, Florida, United States
Solutions Through Advanced Research, Inc.
🇺🇸
Jacksonville, Florida, United States
Advanced Medical Research
🇺🇸
Sandy Springs, Georgia, United States
Forward Clinical Trials, Inc
🇺🇸
Tampa, Florida, United States
Arlington Dermatology
🇺🇸
Rolling Meadows, Illinois, United States
University of Chicago Medical Center
🇺🇸
Chicago, Illinois, United States
The South Bend Clinic
🇺🇸
South Bend, Indiana, United States
SSM Health Cardinal Glennon Children's Hospital
🇺🇸
Saint Louis, Missouri, United States
Ohio State Univ College Of Medicine
🇺🇸
Gahanna, Ohio, United States
Psoriasis Treatment Center of Central New Jersey
🇺🇸
East Windsor, New Jersey, United States
Wright State Physicians Dermatology
🇺🇸
Fairborn, Ohio, United States
University of North Carolina Dermatology and skin Cancer Cen
🇺🇸
Chapel Hill, North Carolina, United States
Dermatology and Skin Surgery Center
🇺🇸
Exton, Pennsylvania, United States
Virginia Clinical Research
🇺🇸
Norfolk, Virginia, United States
Centro de Investigaciones Metabólicas (CINME)
🇦🇷
Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina
Fundación Estudios Clínicos- Servicio de Dermatología
🇦🇷
Rosario, Santa Fe, Argentina
Instituto de Neumonología y Dermatología
🇦🇷
Buenos Aires, Argentina
Psoriahue Medicina Interdisciplinaria
🇦🇷
Buenos Aires, Argentina
Institute for Skin Advancement
🇨🇦
Calgary, Alberta, Canada
Lynderm Research Inc
🇨🇦
Markham, Ontario, Canada
K. Papp Clinical Research Inc
🇨🇦
Waterloo, Ontario, Canada
Detska fakultni nemocnice
🇨🇿
Brno, Czechia
Hospital Ste Justine
🇨🇦
Montreal, Quebec, Canada
Fakultni nemocnice Hradec Kralove
🇨🇿
Hradec Kralove, Czechia
Nemocnice Na Bulovce
🇨🇿
Praha 8, Czechia
LF UK - Fakultni poliklinika
🇨🇿
Praha, Czechia
Fakultni Nemocnice Plzen
🇨🇿
Plzen-Bory, Czechia
Fakultni nemocnice Kralovske Vinohrady
🇨🇿
Praha 10, Czechia
Centre hospitalier universitaire Pellegrin
🇫🇷
Bordeaux, France
CHU de Nice Hopital de L'Archet
🇫🇷
Nice, France
Hôpital Femme Mère Enfant
🇫🇷
Bron, France
Universitätsklinikum Erlangen
🇩🇪
Erlangen, Bayern, Germany
Klinikum der Johann Wolfgang Goethe-Universität Frankfurt
🇩🇪
Frankfurt am Main, Hessen, Germany
ISA GmbH
🇩🇪
Berlin, Germany
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
🇩🇪
Mainz, Rheinland-Pfalz, Germany
Universitätsklinikum Münster
🇩🇪
Münster, Nordrhein-Westfalen, Germany
SZTE AOK Borgyogyaszati es Allergologiai Klinika
🇭🇺
Szeged, Csongrad, Hungary
Debreceni Egyetem Klinikai Kozpont Borgyogyaszati Klinika
🇭🇺
Debrecen, Hajdu-Bihar, Hungary
Allergo-Derm Bakos Kft
🇭🇺
Szolnok, Jasz-Nagykun-Szolnok, Hungary
Oroshaza Varosi Onkormanyzat Korhaza
🇭🇺
Oroshaza, Hungary
Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak
🇭🇺
Budapest, Hungary
Hospital Infantil de Mexico
🇲🇽
Ciudad de Mexico, Federal District, Mexico
Arke Estudios Clinicos S.A. de C.V.
🇲🇽
Veracruz, Mexico
Universitair Medisch Centrum St Radboud Nijmegen
🇳🇱
Nijmegen, Netherlands
"Dermed" Centrum Medyczne Sp. z o.o.
🇵🇱
Lodz, Poland
Centralny Szpital Kliniczny MSW
🇵🇱
Warszawa, Poland
DermMEDICA Sp. z o.o.
🇵🇱
Wroclaw, Poland
Ponce School of Medicine CAIMED Center
🇵🇷
Ponce, Puerto Rico
GBUZ Clinical dermatology and venereological dispensary
🇷🇺
Krasnodar, Russian Federation
Center of Children's Health
🇷🇺
Moscow, Russian Federation
Hospital Sant Joan de Déu
🇪🇸
Esplugues de Llobregat, Barcelona, Spain
Hospital Universitario 12 de Octubre
🇪🇸
Madrid, Spain
Hospital Universitario La Paz
🇪🇸
Madrid, Spain
University of Missouri
🇺🇸
Columbia, Missouri, United States